Clinical Research
News & Careers
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile


Boehringer Ingelheim Pharmaceuticals, Inc. 

900 Ridgebury Road

Ridgefield  Connecticut  06877  U.S.A.
Phone: 203-798-9988 Fax: n/a


About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.

In 2010, Boehringer Ingelheim posted net sales of approximately $16.7 billion (about 12.6 billion euro) while spending almost 24% of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information, please visit and follow us on Twitter at

Value Through Innovation

Our vision of Value through Innovation (VTI) guides our way of working together. It helps us build on our strength and make the most of our distinctive character, enabling us individually and collectively to achieve great success. It also helps us foster value creation throughout our company and to look to the future with constantly renewed commitment and ambition.

Our Lead & Learn principles outline ways in which we can build on our culture of working together to realize and deliver Value through Innovation. These principles encourage us to take risks, ask questions, and seize opportunities in an environment of shared leadership and learning.

Our Success Depends on our People

For more than 125 years, the commitment, innovative-thinking and creative power of our people has made Boehringer Ingelheim one of the fastest growing pharmaceutical companies and an employer of choice. Our workplace reflects our distinctive and innovative culture, built on a foundation of mutual respect and fairness.

We have high expectations and require employees at all levels of the organization to take initiative, stay connected, grow together and achieve outstanding results. To enable this high performance we provide opportunities for personal growth, a collaborative and inclusive work environment and exceptional employee benefits and we reward high achievement with recognition, opportunities and competitive pay.

Driven by a Different Philosophy

We realize that our strength and competitive advantage lie with our people. We support our employees in a number of ways to create a healthy working environment, meaningful work, diversity, mobility, networking and work-life balance.

In a world where business is too often driven by short-term financial goals, Boehringer Ingelheim is truly a company with a different philosophy. As one of the fastest growing pharmaceutical companies in the world, our focus is on helping patients, serving our customers and improving the quality of life for the millions of people who rely on us. Simply put, we remain committed to doing the right thing – for our customers, our communities, our employees and everyone we serve.

Because our products enhance millions of lives, our employees experience the satisfaction of doing important work. Their achievements bring them recognition, and opportunities for career growth. We invite you to join us in improving lives worldwide.

 Key Statistics

Ownership: Private

Web Site: Boehringer Ingelheim Pharmaceuticals, Inc.
Employees: More than 9,000 Employees in the US; 42,000 Worldwide

 Company News
Boehringer Ingelheim Pharmaceuticals, Inc.'s Investigational Biologic Cleared Skin Better Than Ustekinumab In Head-To-Head Phase II Psoriasis Study 3/20/2015 11:32:25 AM
New Data From Boehringer Ingelheim Pharmaceuticals, Inc.'s GLORIA-AF Registry Show Non-Valvular Atrial Fibrillation (NVAF) Patients At High Risk Of Stroke May Be Undertreated 3/16/2015 7:33:07 AM
Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Survey Uncovers Emotional And Physical Impact Of Idiopathic Pulmonary Fibrosis, A Fatal Lung Disease 2/12/2015 7:34:00 AM
Boehringer Ingelheim Pharmaceuticals, Inc. Launches Groundbreaking Initiative "Cuida tu Don" With Entertainer "Don Francisco" Aimed At Hispanics With Type 2 Diabetes 2/10/2015 11:53:58 AM
Boehringer Ingelheim Pharmaceuticals, Inc. Release: SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray Now Available In The United States 1/21/2015 7:43:12 AM
Boehringer Ingelheim Pharmaceuticals, Inc. Release: Interim Data Reinforce Safety and Effectiveness of Pradaxa (dabigatran etexilate mesylate) versus Warfarin in Routine Care of Patients with Non-valvular Atrial Fibrillation 11/18/2014 2:40:16 PM
Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Data Show Idarucizumab* Restores Wound-Site Formation Of Fibrin, A Key Component Of Blood Clotting, In Healthy Volunteers Given Pradaxa (dabigatran etexilate mesylate) 11/18/2014 2:39:01 PM
Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Data Show Idarucizumab* Reverses Anticoagulant Effects Of Dabigatran (PRADAXA) In Middle-Aged, Elderly And Renally Impaired Volunteers 11/10/2014 10:25:49 AM
Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Real-World Safety And Efficacy Data On Pradaxa® (dabigatran etexilate mesylate) To Be Presented At American Heart Association Scientific Sessions 11/10/2014 9:34:15 AM
Boehringer Ingelheim Pharmaceuticals, Inc. Announces U.S. Filing Acceptance Of New Drug Application For Spiriva® Respimat® (Tiotropium Bromide) Inhalation Spray For The Treatment Of Asthma 11/3/2014 8:39:55 AM